These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 27070040)

  • 1. Correlates of Prescription Opioid Legitimacy Judgments Among Community Pharmacists.
    Hagemeier NE; Alamian A; Murawski MM; Flippin H; Hagy EJ; Pack RP
    Subst Use Misuse; 2016 May; 51(6):692-9. PubMed ID: 27070040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Theoretical exploration of Tennessee community pharmacists' perceptions regarding opioid pain reliever abuse communication.
    Hagemeier NE; Murawski MM; Lopez NC; Alamian A; Pack RP
    Res Social Adm Pharm; 2014; 10(3):562-75. PubMed ID: 23981913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacists Who Screen and Discuss Opioid Misuse With Patients: Future Directions for Research and Practice.
    Cochran G; Field C; Lawson K
    J Pharm Pract; 2015 Aug; 28(4):404-12. PubMed ID: 24532819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges faced with opioid prescriptions in the community setting - Australian pharmacists' perspectives.
    Makdessi CJ; Day C; Chaar BB
    Res Social Adm Pharm; 2019 Aug; 15(8):966-973. PubMed ID: 30819418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Examination of why some community pharmacists do not provide 72-hour emergency prescription drugs to Medicaid patients when prior authorization is not available.
    Shepherd MD
    J Manag Care Pharm; 2013 Sep; 19(7):523-33. PubMed ID: 23964613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What predicts pharmacists' engagement with opioid-outcome screening? Secondary analysis from an implementation study in community pharmacy.
    Nielsen S; Sanfilippo P; Picco L; Bruno R; Kowalski M; Wood P; Larney S
    Int J Clin Pharm; 2021 Apr; 43(2):420-429. PubMed ID: 32533428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacists' nonprescription syringe dispensing perceptions and behaviors: A three-state descriptive analysis.
    Hagemeier NE; Dowling-McClay K; Baladezaei M; Curtis SJ; Spence M
    Drug Alcohol Depend; 2021 Apr; 221():108597. PubMed ID: 33631542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacists' training, perceived roles, and actions associated with dispensing controlled substance prescriptions.
    Fleming ML; Barner JC; Brown CM; Shepherd MD; Strassels SA; Novak S
    J Am Pharm Assoc (2003); 2014; 54(3):241-50. PubMed ID: 24816350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Community pharmacists' prescription intervention practices--exploring variations in practice in Norwegian pharmacies.
    Mandt I; Horn AM; Ekedahl A; Granas AG
    Res Social Adm Pharm; 2010 Mar; 6(1):6-17. PubMed ID: 20188324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of community chain pharmacists' interventions on electronic prescriptions.
    Warholak TL; Rupp MT
    J Am Pharm Assoc (2003); 2009; 49(1):59-64. PubMed ID: 19196598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integration of prescription drug monitoring programs (PDMP) in pharmacy practice: Improving clinical decision-making and supporting a pharmacist's professional judgment.
    Norwood CW; Wright ER
    Res Social Adm Pharm; 2016; 12(2):257-66. PubMed ID: 26143489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns, Changes, and Trends in Prescription Opioid Dispensing in Canada, 2005-2016.
    Fischer B; Jones W; Vojtila L; Kurdyak P
    Pain Physician; 2018 May; 21(3):219-228. PubMed ID: 29871366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Community pharmacists' preparedness to intervene with concerns around prescription opioids: findings from a nationally representative survey.
    Alvin M; Picco L; Wood P; Mnatzaganian G; Nielsen S
    Int J Clin Pharm; 2021 Apr; 43(2):411-419. PubMed ID: 32951182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of concentration ratios to analyze the phenomenon of "next-door" pharmacy in Taiwan.
    Ji Chen T; Chou LF; Hwang SJ
    Clin Ther; 2006 Aug; 28(8):1225-1230. PubMed ID: 16982300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibiotic dispensation by Lebanese pharmacists: a comparison of higher and lower socio-economic levels.
    Farah R; Lahoud N; Salameh P; Saleh N
    J Infect Public Health; 2015; 8(1):37-46. PubMed ID: 25139454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of costs to dispense prescriptions in independently owned, closed-door long-term care pharmacies.
    Carroll NV; Rupp MT; Holdford DA
    J Manag Care Spec Pharm; 2014 Mar; 20(3):291-300. PubMed ID: 24564809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacists' readiness to provide naloxone in community pharmacies in West Virginia.
    Thornton JD; Lyvers E; Scott VGG; Dwibedi N
    J Am Pharm Assoc (2003); 2017; 57(2S):S12-S18.e4. PubMed ID: 28163027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using the theory of planned behavior to examine pharmacists' intention to utilize a prescription drug monitoring program database.
    Fleming ML; Barner JC; Brown CM; Shepherd MD; Strassels S; Novak S
    Res Social Adm Pharm; 2014; 10(2):285-96. PubMed ID: 23816495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of pharmacies and pharmacists in managing controlled substance dispensing.
    Hoppe J; Howland MA; Nelson L
    Pain Med; 2014 Dec; 15(12):1996-8. PubMed ID: 25138390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of unmet demand for pharmacists: a survey of rural community pharmacies in Wisconsin.
    Gadkari AS; Mott DA; Kreling DH; Bonnarens JK
    J Am Pharm Assoc (2003); 2008; 48(5):598-609. PubMed ID: 18826899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.